Mycal Dutta | Pharmaceutical Science | Best Researcher Award

Dr. Mycal Dutta | Pharmaceutical Science | Best Researcher Award

Associate Professor at University of Science and Technology (USTC), Bangladesh

Dr. Mycal Dutta is an accomplished Associate Professor in the Department of Pharmacy at the University of Science and Technology Chittagong (USTC), Bangladesh. With nearly fourteen years of experience in academia, research, and professional practice, he has made significant contributions to pharmaceutical sciences. Dr. Dutta earned his Ph.D. in Pharmacy from Jahangirnagar University, Dhaka, in December 2022. His expertise spans pharmaceutical technology, microbiology, and clinical pharmacy. He has published 36 research papers in national and international journals, focusing on bioactive phytochemicals, drug formulation, and pharmacological investigations. As a registered “A” Grade Pharmacist, he actively contributes to professional training and advisory committees. His research interests include the isolation of medicinal plant compounds, computational drug design, and molecular docking studies. Dr. Dutta has received several research grants, including government-funded projects on ethnomedicinal plants. Apart from his academic roles, he has been involved in organizing scientific conferences and student welfare activities. His commitment to teaching, research, and pharmaceutical advancements has made him a distinguished figure in the field.

Professional Profile

Education

Dr. Mycal Dutta has a strong academic background in pharmacy. He obtained his Ph.D. in Pharmacy from Jahangirnagar University, Dhaka, in December 2022. Prior to this, he completed his Master of Pharmacy (Thesis) degree from Southern University, Bangladesh, in 2011, achieving a CGPA of 3.6 on a 4.0 scale. He earned his Bachelor of Pharmacy (Hons.) degree from the University of Science and Technology Chittagong (USTC) in 2009, graduating with First Class honors. His foundational education includes a Higher Secondary Certificate (HSC) from Govt. Hazi Muhammad Mohsin College, Chittagong, with a GPA of 4.70 out of 5.00 in 2004, and a Secondary School Certificate (SSC) from Collegiate School, Chittagong, with a GPA of 4.38 out of 5.00 in 2002. His educational journey reflects his dedication to academic excellence and pharmaceutical sciences.

Professional Experience

Dr. Mycal Dutta has extensive teaching and research experience in the field of pharmacy. He has been serving as an Associate Professor at the University of Science and Technology Chittagong (USTC) since July 2023. Previously, he worked as an Assistant Professor at BGC Trust University Bangladesh for nearly eight years (2015–2023) and as a Lecturer at the same institution for almost five years (2011–2015). In addition to his teaching roles, he has contributed significantly to academic administration, including serving as an advisor in the Student Welfare Advisory Committee at USTC and as Chief Advisor of the Career Development and Placement Club at BGC Trust University. His professional contributions extend to chairing scientific and publication committees for national conferences and participating in examination committees. His vast experience demonstrates his dedication to pharmacy education and academic leadership.

Research Interests

Dr. Mycal Dutta’s research interests focus on pharmacological and phytochemical investigations of medicinal plants. His work involves compound isolation using techniques such as Nuclear Magnetic Resonance (NMR) and Gas Chromatography-Mass Spectrometry (GC-MS). He is particularly interested in computational drug discovery, molecular docking, Quantitative Structure-Activity Relationship (QSAR) modeling, and ADME/T property analysis of natural compounds. His research aims to bridge wet lab and dry lab approaches to develop therapeutic solutions from natural products. He also explores antimicrobial studies, aseptic techniques, bacterial staining, and in vitro and in vivo pharmacological investigations. His research contributions significantly advance the understanding of bioactive phytochemicals and their therapeutic potential.

Research Skills

Dr. Mycal Dutta possesses a diverse range of research skills, including microbiological techniques such as aseptic handling, bacterial staining, and antimicrobial sensitivity testing. He is proficient in computational drug design, protein modeling, and molecular simulations. His technical expertise extends to animal research, including transgenic and knockout mouse models. He is skilled in using various molecular modeling and Computer-Aided Drug Design (CADD) software. Additionally, he has extensive experience with statistical analysis tools such as GraphPad Prism and SPSS. His proficiency in these areas enables him to conduct high-quality research and mentor students in advanced pharmaceutical investigations.

Awards and Honors

Dr. Mycal Dutta has received several prestigious research grants and recognitions. He was awarded the R&D Grant for Science and Technology (2022–2023) from the Ministry of Science and Technology, Bangladesh, for his research on bioactive phytochemicals. Additionally, he secured a research grant from BGC Trust University Bangladesh in 2017 to support his Ph.D. research. His contributions to pharmaceutical research have been acknowledged through numerous publications in high-impact journals. He has also played a key role in organizing national conferences and scientific symposiums. His commitment to research and academia has earned him a strong reputation in the field of pharmaceutical sciences.

Conclusion

Dr. Mycal Dutta is a dedicated researcher, educator, and pharmaceutical scientist committed to advancing pharmaceutical education and research. With nearly fourteen years of experience, he has made remarkable contributions to pharmacology, phytochemistry, and drug discovery. His extensive research on medicinal plants and computational drug design has positioned him as a leading expert in the field. His passion for teaching, mentoring students, and conducting groundbreaking research continues to impact the pharmaceutical sciences significantly. Through his academic leadership, professional affiliations, and research initiatives, he remains at the forefront of pharmaceutical innovation and education.

Publications Top Notes

  1. Yusuf, A., Shaikat, M. A., Bhuiya, M. A. M., Dutta, M., Nath, A. K., & Dash, P. R. (2023). Utilizing the Medicinal Properties of Delonix regia for Diseases and Beyond: A Review of its Phytochemistry and Pharmacology. Tropical Journal of Natural Product Research, 7(12), 5355–5365. DOI: 10.26538/tjnpr/v7i12.2

  2. Malini, S., Raj, K., Madhumathy, S., El-Hady, K. M., Islam, S., & Dutta, M. (2022). Bioinspired Advances in Nanomaterials for Sustainable Agriculture. Journal of Nanomaterials, 2022, Article ID 8926133. DOI: 10.1155/2022/8926133

  3. Vaidya, S., Jeengar, M., Wadaan, M. A., Mahboob, S., Kumar, P., Reece, L. M., Bathula, S. R., & Dutta, M. (2022). Design and In Vitro Evaluation of Novel Cationic Lipids for siRNA Delivery in Breast Cancer Cell Lines. Evidence-Based Complementary and Alternative Medicine, 2022, Article ID 9231641. DOI: 10.1155/2022/9231641

  4. Jadhav, V., Bhagare, A., Wahab, S., Lokhande, D., Vaidya, C., Dhayagude, A., Khalid, M., Aher, J., Mezni, A., & Dutta, M. (2022). Green Synthesized Calcium Oxide Nanoparticles (CaO NPs) Using Leaves Aqueous Extract of Moringa oleifera and Evaluation of Their Antibacterial Activities. Journal of Nanomaterials, 2022, Article ID 9047507. DOI: 10.1155/2022/9047507

  5. Jadhav, V., Bhagare, A., Ali, I. H., Dhayagude, A., Lokhande, D., Aher, J., Jameel, M., & Dutta, M. (2022). Role of Moringa oleifera on Green Synthesis of Metal/Metal Oxide Nanomaterials. Journal of Nanomaterials, 2022, Article ID 2147393. DOI: 10.1155/2022/2147393

  6. Alharthy, S. A., Shams Tabrez, S., Ahmed A. Mirza, A. A., Torki A. Zughaibi, Firoz, C. K., & Dutta, M. (2022). Sugiol Suppresses the Proliferation of Human U87 Glioma Cells via Induction of Apoptosis and Cell Cycle Arrest. Evidence-Based Complementary and Alternative Medicine, 2022, Article ID 7658899. DOI: 10.1155/2022/7658899

  7. Dutta, M., Akter, T., Nezam, M., Paul, A., & Rana, M. S. (2022). In silico Molecular Docking and ADME/T Analysis of Selected Bioactive Compounds from Leucas zeylanica against Breast Cancer. BGC Trust University Journal, 6, 51–66.

  8. Dutta, M., Tareq, A. M., Rakib, A., Mahmud, S., Sami, S. A., Mallick, J., Islam, M. N., Majumder, M., Uddin, M. Z., Alsubaie, A., & Almalki, A. S. (2021). Phytochemicals from Leucas zeylanica Targeting Main Protease of SARS-CoV-2: Chemical Profiles, Molecular Docking, and Molecular Dynamics Simulations. Biology, 10(8), 789. DOI: 10.3390/biology10080789

  9. Dutta, M., Nezam, M., Chowdhury, S., Rakib, A., Paul, A., Sami, S. A., Uddin, M. Z., Rana, M. S., Hossain, S., Effendi, Y., Idroes, R., Tallei, T. E., Alqahtani, A. M., & Emran, T. B. (2021). Appraisals of the Bangladeshi Medicinal Plant Calotropis gigantea Used by Folk Medicine Practitioners in the Management of COVID-19: A Biochemical and Computational Approach. Frontiers in Molecular Biosciences, 8, 625391. DOI: 10.3389/fmolb.2021.625391

  10. Rakib, A., Paul, A., Ahmed, S., Chy, M. N. U., Baral, S. K., Majumder, M., Tareq, A. T., Amin, M. N., Shahriar, A., Uddin, M. Z., Dutta, M., Tallei, T. E., Emran, T. B., & Simal-Gandara, J. (2020). Biochemical and Computational Approach of Phytocompounds from Tinospora crispa in the Management of COVID-19: Molecules; 25(17): E3936. DOI: 10.3390/molecules25173936

Ronit Satchi-Fainaro | Pharmacology | Outstanding Scientist Award

Prof Dr. Ronit Satchi-Fainaro | Pharmacology | Outstanding Scientist Award

 Cancer Biology Research Center at Tel Aviv University, Israel

Ronit Satchi-Fainaro is a prominent figure in cancer research, currently serving as a Full Professor in the Department of Physiology and Pharmacology at Tel Aviv University and Director of the Cancer Biology Research Center. With a Ph.D. in polymer chemistry and extensive postdoctoral training at renowned institutions, her research focuses on cancer biology, tumor dormancy, and the development of targeted nanomedicines. Satchi-Fainaro has pioneered multi-modality polymer therapeutics that combine anti-angiogenic agents with chemotherapeutics, significantly advancing the field of cancer treatment. Her impressive publication record includes groundbreaking articles in Nature Medicine and Cancer Cell, and she has filed multiple patents for her innovative findings. Additionally, she has received numerous accolades for her contributions to science, including the Humboldt Foundation Bessel Research Prize. Satchi-Fainaro’s leadership in interdisciplinary research and commitment to translating scientific discoveries into clinical applications make her a leading voice in modern cancer therapeutics.

Professional Profile

Education

Ronit Satchi-Fainaro has an impressive educational background that laid the foundation for her distinguished career in pharmacology and cancer research. She earned her Bachelor of Pharmacy (B.Pharm.) degree in Pharmacology from The Hebrew University, Faculty of Medicine, School of Pharmacy, in June 1995. Following her undergraduate studies, she completed an internship in Industrial Pharmacy at Perio Products Ltd. in Jerusalem in March 1996. Satchi-Fainaro then pursued her Ph.D. at the University of London, specializing in polymer chemistry, biochemistry, and cancer nanomedicine. Her doctoral research, titled “PDEPT: Polymer Directed Enzyme Prodrug Therapy,” was completed in November 1999 under the supervision of Prof. Ruth Duncan. Subsequently, she expanded her expertise through postdoctoral fellowships at Tel Aviv University and Harvard Medical School, focusing on tumor biology, molecular biology, and protein delivery, further solidifying her status as a leader in the field of cancer research and nanomedicine.

 

Professional Experience

Ronit Satchi-Fainaro is a distinguished Full Professor in the Department of Physiology and Pharmacology at Tel Aviv University and serves as the Director of the Cancer Biology Research Center. With over 15 years of leadership at the university, she has spearheaded a multidisciplinary research group focused on innovative cancer therapies. Satchi-Fainaro’s expertise encompasses polymer chemistry, biochemistry, and nanomedicine, leading to the development of targeted polymer therapeutics and nano-vaccines. She has collaborated with prominent institutions, including Harvard Medical School, where she contributed to significant advances in tumor biology and angiogenesis. Her entrepreneurial spirit is evident through her co-founding of biotech companies, such as ImmuNovation, Ltd., and her active role on various scientific advisory boards. Satchi-Fainaro has garnered numerous accolades, including the Humboldt Foundation Bessel Research Prize, reflecting her substantial impact in cancer research and drug delivery systems. Her work continues to push the boundaries of personalized medicine and cancer therapeutics

Research Interests

Ronit Satchi-Fainaro’s research interests lie at the intersection of cancer biology, pharmacology, and nanomedicine. She focuses on understanding the mechanisms underlying cancer dormancy and the tumor-host interactions that facilitate metastasis. Her innovative work involves developing targeted nanomedicines that integrate anti-stromal agents with chemotherapeutics to enhance treatment efficacy while reducing toxicity. Satchi-Fainaro’s laboratory employs advanced techniques such as molecular imaging, 3D bioprinted cancer models, and personalized theranostics to investigate tumor biology and angiogenesis. She aims to identify molecular signatures that predict tumor behavior and survivorship, driving the rational design of novel therapeutic approaches. Additionally, her interdisciplinary approach combines elements of biology, chemistry, engineering, and material sciences, facilitating the development of highly selective drug delivery systems. Through her pioneering research, Satchi-Fainaro aspires to contribute to more effective cancer therapies and improve patient outcomes in the fight against cancer.

Ronit Satchi-Fainaro has received numerous prestigious awards and honors throughout her distinguished career, reflecting her significant contributions to cancer research and nanomedicine. Notable accolades include the British Council Chevening Award, the Nagai Foundation Graduate Student Award, and the Fulbright Scholarship. She was recognized as a “Person of the Year” in Medicine by Forbes Israel and included in various influential lists, such as the “50 Most Influential Women” and “40 Under 40” by prominent Israeli journals. In addition, she has received the ERC Advanced Grant, the 3D Printing Industry Award for Medical Application of the Year, and the Bessel Research Prize from the Humboldt Foundation. Her work has garnered multiple research prizes for exceptional publications at Tel Aviv University and recognition as a Fellow of the American Institute of Medical and Biological Engineers (AIMBE). These accolades highlight her impactful research and leadership in advancing innovative cancer therapies.

 

Conclusion

Ronit Satchi-Fainaro is a distinguished leader in cancer research, whose innovative work in nanomedicine has significantly advanced the understanding and treatment of cancer. With a robust academic background and over 15 years at Tel Aviv University, she has successfully led multidisciplinary research initiatives that tackle complex questions in tumor biology and drug delivery. Her pioneering development of multi-modality targeted nanomedicines has not only garnered numerous patents but also positioned her at the forefront of translational research. Satchi-Fainaro’s impressive publication record in high-impact journals, coupled with her numerous accolades—including the Humboldt Foundation Bessel Research Prize—underscores her contributions to science. As the Director of the Cancer Biology Research Center, she exemplifies a commitment to fostering collaboration and mentorship in the scientific community. Overall, her accomplishments and dedication to improving cancer therapies make her a highly deserving candidate for the Research for Outstanding Scientist Award.

 

Publication top noted
  • Title: interFLOW: maximum flow framework for the identification of factors mediating the signaling convergence of multiple receptors
    Authors: Sheinin, R., Salomon, K., Yeini, E., Sharan, R., Madi, A.
    Year: 2024
    Citations: 0
  • Title: Polyester nanoparticles delivering chemotherapeutics: Learning from the past and looking to the future to enhance their clinical impact in tumor therapy
    Authors: Longobardi, G., Moore, T.L., Conte, C., Satchi-Fainaro, R., Quaglia, F.
    Year: 2024
    Citations: 0
  • Title: Multifunctional Nanovaccine Sensitizes Breast Cancer to Immune Checkpoint Therapy
    Authors: Peres, C., Matos, A.I., Carreira, B., Satchi-Fainaro, R., Florindo, H.F.
    Year: 2024
    Citations: 2
  • Title: Combining TIGIT Blockade with MDSC Inhibition Hinders Breast Cancer Bone Metastasis by Activating Antitumor Immunity
    Authors: Monteran, L., Ershaid, N., Scharff, Y., Zhang, X.H.-F., Erez, N.
    Year: 2024
    Citations: 3
  • Title: The role of CCL2/CCR2 axis in cancer and inflammation: The next frontier in nanomedicine
    Authors: Pozzi, S., Satchi-Fainaro, R.
    Year: 2024
    Citations: 3
  • Title: Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker
    Authors: Liubomirski, Y., Tiram, G., Scomparin, A., Shabat, D., Satchi-Fainaro, R.
    Year: 2024
    Citations: 3
  • Title: Intranasal Multiepitope PD-L1-siRNA-Based Nanovaccine: The Next-Gen COVID-19 Immunotherapy
    Authors: Acúrcio, R.C., Kleiner, R., Vaskovich-Koubi, D., Florindo, H.F., Satchi-Fainaro, R.
    Year: 2024
    Citations: 0
  • Title: Polyoxazoline-Based Nanovaccine Synergizes with Tumor-Associated Macrophage Targeting and Anti-PD-1 Immunotherapy against Solid Tumors
    Authors: Matos, A.I., Peres, C., Carreira, B., Satchi-Fainaro, R., Florindo, H.F.
    Year: 2023
    Citations: 6
  • Title: Deoxyhypusine hydroxylase: A novel therapeutic target differentially expressed in short-term vs long-term survivors of glioblastoma
    Authors: Ofek, P., Yeini, E., Arad, G., Geiger, T., Satchi-Fainaro, R.
    Year: 2023
    Citations: 4
  • Title: Development of Chitosan Particles Loaded with siRNA for Cystatin C to Control Intracellular Drug-Resistant Mycobacterium tuberculosis
    Authors: Pires, D., Mandal, M., Matos, A.I., Florindo, H.F., Anes, E.
    Year: 2023
    Citations: 6